세계의 다발성 근염 시장 보고서(2025년)

Polymyositis is a chronic inflammatory myopathy that causes progressive muscle weakness, primarily affecting the skeletal muscles. It results from an autoimmune response in which the body's immune system mistakenly attacks muscle fibers, leading to inflammation, degeneration, and weakness.

The main types of polymyositis include idiopathic polymyositis, dermatomyositis, inclusion body myositis, and overlapping myositis syndromes. Idiopathic polymyositis is a rare muscle disease characterized by weakness and inflammation, typically treated with corticosteroids. Diagnosis is made through various methods, including physical examination, muscle biopsy, electromyography (EMG), blood tests, and magnetic resonance imaging (MRI). Treatments for the condition include immunosuppressants, immunoglobulins, corticosteroids, alkylating agents, monoclonal antibodies, and other medications. These treatments are distributed through various channels, such as offline and online, and are utilized by different end users, including hospital pharmacies, online pharmacies, and retail pharmacies.

The polymyositis market research report is one of a series of new reports from The Business Research Company that provides polymyositis market statistics, including the polymyositis industry global market size, regional shares, competitors with the polymyositis market share, detailed polymyositis market segments, market trends, and opportunities, and any further data you may need to thrive in the polymyositis industry. This polymyositis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The polymyositis market size has grown strongly in recent years. It will grow from $1.65 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to increased access in developing regions, greater use of prednisone, the rising popularity of methotrexate for managing symptoms, a growing reliance on TNF inhibitors, and an increase in the use of antibody testing.

The polymyositis market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to the expansion of telemedicine, increased use of remote monitoring, growing use of immunosuppressants, a rise in stem cell therapy, and increased adoption of biosimilars. Key trends during this period include the integration of artificial intelligence in drug discovery, advancements in targeted therapies, the development of novel immunomodulators, rising research in regenerative medicine, and the integration of big data.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the polymyositis market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, causing inflammation and damage. The prevalence of these conditions is rising due to certain genetic variants that can trigger an overactive immune response, making individuals more likely to attack their own tissues. This genetic predisposition, combined with environmental factors such as infections, stress, and lifestyle choices, contributes to the growing incidence of autoimmune diseases. Polymyositis contributes to the understanding of autoimmune diseases by demonstrating how immune system dysfunction causes muscle inflammation, providing insights into the mechanisms of related conditions and potential treatments. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, reflecting a raw prevalence rate of 8.61%. As such, the increasing prevalence of autoimmune diseases is driving the polymyositis market.

The rising demand for oral drugs is expected to further accelerate the growth of the polymyositis market. Oral drugs are medications taken by mouth in the form of tablets, capsules, or liquids, which are absorbed through the digestive system. The growing preference for oral drugs is due to their convenience, ease of use, and non-invasive nature, making them a preferred option over injections or other forms of medication delivery. Polymyositis is often treated with oral drugs that help reduce muscle inflammation, regulate the immune system, and improve muscle function, which helps alleviate symptoms and prevent disease progression. For instance, in October 2022, the Centers for Disease Control and Prevention (CDC) reported a 57% increase in the dispensing of oral antivirals, from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. This increase in demand for oral drugs is contributing to the growth of the polymyositis market.

Companies operating in the polymyositis market are focusing on innovative therapies such as stem cell therapy to improve treatment outcomes and slow disease progression. Stem cell therapy involves using umbilical cord-derived stem cells for regenerative treatments. These stem cells have strong immunomodulatory and anti-inflammatory properties, making them a promising option for treating autoimmune diseases such as polymyositis. For example, in December 2024, RESTEM, a U.S.-based clinical-stage biotechnology company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its stem cell program, which uses umbilical cord outer lining stem cells (ULSCs) to treat polymyositis and Dermatomyositis. This therapy works by regulating the immune system and reducing muscle inflammation. Early trials have shown promising safety and efficacy, with the potential to reduce dependency on steroids.

Major players in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited.

North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in polymyositis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the polymyositis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The polymyositis market consists of revenues earned by entities by providing services such as diagnosis and testing services, pharmacological treatment services, physical therapy and rehabilitation services, and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyositis market also includes sales of anti-inflammatory and pain management medications, biologic therapies, intravenous immunoglobulin (IVIG) therapy, and plasmapheresis (plasma exchange) products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Polymyositis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on polymyositis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for polymyositis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The polymyositis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Idiopathic Polymyositis; Dermatomyositis; Inclusion Body Myositis; Overlapping Myositis Syndromes
• 2) By Diagnosis: Physical Examination; Muscle Biopsy; Electromyography (EMG); Blood Tests; Magnetic Resonance Imaging (MRI)
• 3) By Treatment: Immunosuppressant; Immunoglobulins; Corticosteroids; Alkylating agents; Monoclonal Antibodies
• 4) By Distribution Channel: Offline; Online
• 5) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy
• Sub Segments:
• 1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis; Virus-Associated Polymyositis
• 2) By Dermatomyositis: Classic Dermatomyositis; Amyopathic Dermatomyositis; Juvenile Dermatomyositis
• 3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis; Hereditary Inclusion Body Myopathy
• 4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE); Polymyositis with Rheumatoid Arthritis (RA); Polymyositis with Systemic Sclerosis; Polymyositis with Mixed Connective Tissue Disease (MCTD)
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Polymyositis Market Characteristics

3. Polymyositis Market Trends And Strategies

4. Polymyositis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Polymyositis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Polymyositis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Polymyositis Market Growth Rate Analysis
• 5.4. Global Polymyositis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Polymyositis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Polymyositis Total Addressable Market (TAM)

6. Polymyositis Market Segmentation

• 6.1. Global Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Polymyositis
• Dermatomyositis
• Inclusion Body Myositis
• Overlapping Myositis Syndromes
• 6.2. Global Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Examination
• Muscle Biopsy
• Electromyography (EMG)
• Blood Tests
• Magnetic Resonance Imaging (MRI)
• 6.3. Global Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressant
• Immunoglobulins
• Corticosteroids
• Alkylating agents
• Monoclonal Antibodies
• 6.4. Global Polymyositis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Offline
• Online
• 6.5. Global Polymyositis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital pharmacy
• Online pharmacy
• Retail pharmacy
• 6.6. Global Polymyositis Market, Sub-Segmentation Of Idiopathic Polymyositis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune-Mediated Polymyositis
• Virus-Associated Polymyositis
• 6.7. Global Polymyositis Market, Sub-Segmentation Of Dermatomyositis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Dermatomyositis
• Amyopathic Dermatomyositis
• Juvenile Dermatomyositis
• 6.8. Global Polymyositis Market, Sub-Segmentation Of Inclusion Body Myositis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sporadic Inclusion Body Myositis
• Hereditary Inclusion Body Myopathy
• 6.9. Global Polymyositis Market, Sub-Segmentation Of Overlapping Myositis Syndromes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymyositis with Systemic Lupus Erythematosus (SLE)
• Polymyositis with Rheumatoid Arthritis (RA)
• Polymyositis with Systemic Sclerosis
• Polymyositis with Mixed Connective Tissue Disease (MCTD)

7. Polymyositis Market Regional And Country Analysis

• 7.1. Global Polymyositis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Polymyositis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Polymyositis Market

• 8.1. Asia-Pacific Polymyositis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Polymyositis Market

• 9.1. China Polymyositis Market Overview
• 9.2. China Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Polymyositis Market

• 10.1. India Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Polymyositis Market

• 11.1. Japan Polymyositis Market Overview
• 11.2. Japan Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Polymyositis Market

• 12.1. Australia Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Polymyositis Market

• 13.1. Indonesia Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Polymyositis Market

• 14.1. South Korea Polymyositis Market Overview
• 14.2. South Korea Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Polymyositis Market

• 15.1. Western Europe Polymyositis Market Overview
• 15.2. Western Europe Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Polymyositis Market

• 16.1. UK Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Polymyositis Market

• 17.1. Germany Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Polymyositis Market

• 18.1. France Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Polymyositis Market

• 19.1. Italy Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Polymyositis Market

• 20.1. Spain Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Polymyositis Market

• 21.1. Eastern Europe Polymyositis Market Overview
• 21.2. Eastern Europe Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Polymyositis Market

• 22.1. Russia Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Polymyositis Market

• 23.1. North America Polymyositis Market Overview
• 23.2. North America Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Polymyositis Market

• 24.1. USA Polymyositis Market Overview
• 24.2. USA Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Polymyositis Market

• 25.1. Canada Polymyositis Market Overview
• 25.2. Canada Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Polymyositis Market

• 26.1. South America Polymyositis Market Overview
• 26.2. South America Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Polymyositis Market

• 27.1. Brazil Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Polymyositis Market

• 28.1. Middle East Polymyositis Market Overview
• 28.2. Middle East Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Polymyositis Market

• 29.1. Africa Polymyositis Market Overview
• 29.2. Africa Polymyositis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Polymyositis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Polymyositis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Polymyositis Market Competitive Landscape And Company Profiles

• 30.1. Polymyositis Market Competitive Landscape
• 30.2. Polymyositis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Polymyositis Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Merck & Co. Inc.
• 31.3. C.H. Boehringer Sohn AG & Co. KG
• 31.4. Regeneron Pharmaceuticals Inc.
• 31.5. Astellas Pharma Inc.
• 31.6. Fresenius SE & Co. KGaA
• 31.7. UCB S.A.
• 31.8. Reliance Life Sciences Private Limited
• 31.9. ARUP Laboratories
• 31.10. Teva Pharmaceuticals USA Inc.
• 31.11. Kezar Life Sciences Inc.
• 31.12. Argenx SE
• 31.13. Mallinckrodt Pharmaceuticals plc
• 31.14. Mitsubishi Tanabe Pharma Corporation
• 31.15. ViiV Healthcare Limited

32. Global Polymyositis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Polymyositis Market

34. Recent Developments In The Polymyositis Market

35. Polymyositis Market High Potential Countries, Segments and Strategies

• 35.1 Polymyositis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Polymyositis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Polymyositis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer